Research Progress on the Role and Mechanism of LncRNA in the Occurrence and Development of Cervical Lesions DOI

邢 张

Advances in Clinical Medicine, Год журнала: 2023, Номер 13(10), С. 15964 - 15969

Опубликована: Янв. 1, 2023

Язык: Английский

The roles and molecular mechanisms of non-coding RNA in cancer metabolic reprogramming DOI Creative Commons
Shizhen Li,

Mingjing Peng,

Shiming Tan

и другие.

Cancer Cell International, Год журнала: 2024, Номер 24(1)

Опубликована: Янв. 18, 2024

Abstract One of the key features cancer is energy metabolic reprogramming which tightly related to proliferation, invasion, metastasis, and chemotherapy resistance. NcRNAs are a class RNAs having no protein-coding potential mainly include microRNAs, lncRNAs circRNAs. Accumulated evidence has suggested that ncRNAs play an essential role in regulating reprogramming, altered networks mediated by primarily drive carcinogenesis expression enzymes transporter proteins. Importantly, accumulated research revealed dysregulated mediate contributing generation therapeutic tolerance. Elucidating molecular mechanism can provide promising metabolism-related targets for treatment as well overcome In conclusion, this review updates latest mechanisms reprogramming.

Язык: Английский

Процитировано

10

METTL3-mediated deficiency of lncRNA HAR1A drives non-small cell lung cancer growth and metastasis by promoting ANXA2 stabilization DOI Creative Commons
Xiaodong Ling,

Cuicui Qi,

Kui Cao

и другие.

Cell Death Discovery, Год журнала: 2024, Номер 10(1)

Опубликована: Апрель 30, 2024

We previously reported lncRNA HAR1A as a tumor suppressor in non-small cell lung cancer (NSCLC). However, the delicate working mechanisms of this remain obscure. Herein, we demonstrated that ectopic expression inhibited proliferation, epithelial-mesenchymal transition (EMT), migration, and invasion NSCLC cells enhanced paclitaxel (PTX) sensitivity vitro vivo. identified oncogenic protein annexin 2 (ANXA2) potential interacting patterner HAR1A. overexpression ANXA2 ubiquitination accelerated its degradation via ubiquitin-proteasome pathway. further uncovered promoted interaction between E3 ubiquitin ligase TRIM65 ANXA2. Moreover, plasmid transfection could reverse overexpression-induced decreases activity NF-κB signaling Finally, found loss might be attributed to upregulated METTL3. The m

Язык: Английский

Процитировано

6

From diagnosis to therapy: The transformative role of lncRNAs in eye cancer management DOI
Ali Hazazi,

Abdulmajid A. AlShehah,

Farhan R. Khan

и другие.

Pathology - Research and Practice, Год журнала: 2024, Номер 254, С. 155081 - 155081

Опубликована: Янв. 3, 2024

Язык: Английский

Процитировано

4

Decoding intricate interactions between m6A modification with mRNAs and non-coding RNAs in cervical cancer: Molecular mechanisms and clinical implications DOI
Xuefei Liu, Lizhi Zhang, Ji Chen

и другие.

Cellular Signalling, Год журнала: 2025, Номер unknown, С. 111745 - 111745

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0

m6A modification of RNA in cervical cancer: role and clinical perspectives DOI Creative Commons
Yajuan Gao, Qi Guo, L.‐C. Yu

и другие.

RNA Biology, Год журнала: 2024, Номер 21(1), С. 49 - 61

Опубликована: Сен. 30, 2024

N6-methyladenosine (m6A) is widely recognized as the predominant form of RNA modification in higher organisms, with capability to finely regulate metabolism, thereby influencing a series crucial physiological and pathological processes. These processes include regulation gene expression, cell proliferation, invasion metastasis, cycle control, programmed death, interactions within tumour microenvironment, energy immune regulation. With advancing research into mechanisms methylation, pivotal role m6A pathophysiology reproductive system tumours, particularly cervical cancer, has been progressively unveiled. This discovery opened new avenues presented significant potential for diagnosis, prognostic evaluation, treatment diseases. review delves deeply biological functions its action onset progression cancer. Furthermore, it explores prospects precision diagnosis aiming provide perspectives theoretical basis innovative advanced strategies

Язык: Английский

Процитировано

2

Epitranscriptomics and cervical cancer: the emerging role of m6A, m5C and m1A RNA modifications DOI
Akshat D. Modi,

Hira Zahid,

Ashlyn Chase Southerland

и другие.

Expert Reviews in Molecular Medicine, Год журнала: 2024, Номер 26

Опубликована: Янв. 1, 2024

Abstract Cervical cancer (CC), one of the most prevalent and detrimental gynaecologic cancers, evolves through genetic epigenetic alterations resulting in promotion oncogenic activity dysfunction tumour-suppressing mechanisms. Despite medical advancement, prognosis for advanced-stage patients remains extremely low due to high recurrence rates resistance existing treatments. Thereby, search potential prognostic biomarkers is heightened unravel new modalities CC pathogenesis develop novel anti-cancer therapies. Epitranscriptomic modifications, reversible RNA regulate various biological processes by deciding fate mediating interactions. This narrative review provides insight into cellular molecular roles endogenous RNA-editing proteins their associated epitranscriptomic especially N 6 -methyladenosine (m A), 5-methylcytosine 5 C) 1 governing development, progression metastasis CC. We discussed in-depth mechanisms underlying regulation over 50 RNAs responsible tumorigenesis, proliferation, migration, invasion, survival, autophagy, stemness, epithelial-mesenchymal transition, metabolism (glucose, lipid, glutamate glutamine), (drug radiation), angiogenesis Additionally, we provided a concise overview therapeutic targeting altered expression aberrant deposition modifications on both coding non-coding

Язык: Английский

Процитировано

2

The ncRNA-TGF-β axis: Unveiling new frontiers in colorectal cancer research DOI
Khalid Saad Alharbi

Pathology - Research and Practice, Год журнала: 2024, Номер 254, С. 155138 - 155138

Опубликована: Янв. 14, 2024

Язык: Английский

Процитировано

1

Transcriptional and post-transcriptional regulation of CARMN and its anti-tumor function in cervical cancer through autophagic flux blockade and MAPK cascade inhibition DOI Creative Commons
Xing Zhang, Wenjing Yan, Hua Jin

и другие.

Journal of Experimental & Clinical Cancer Research, Год журнала: 2024, Номер 43(1)

Опубликована: Ноя. 19, 2024

Abstract Background LncRNAs play essential roles in multiple tumors. However, research on genome-wide lncRNA alterations and their functions cervical cancer (CC) is limited. This study aims to explore key lncRNAs CC progression uncover the molecular mechanisms involved development of CC. Methods In this study, we analyzed 30 tissues from CC, intraepithelial neoplasia (CIN), normal (NOR) using transcriptome sequencing weighted gene co-expression network analysis establish modules related NOR-CIN-CC transition. Machine learning diagnostic models were employed investigate role Molecular biological experiments conducted elucidate potential CARMN with a particular focus its transcriptional post-transcriptional regulation abnormal expression Results was identified as hub two significantly associated Analysis ten machine confirmed critical progression. The results RNA-seq, qPCR RNAScope performed another cohort 83 all showed that downregulated enhanced interaction between Keap1 Nrf2, leading increased ROS levels. elevated levels suppressed Akt/mTOR signaling pathway, autophagy arrest via autophagic flux blockade. Additionally, interacted TFAP2α repress MAPK13 transcription, further inhibiting MAPK cascade. A promoter SNP (rs12517403) found increase risk (OR = 1.34, 95% CI 1.11–1.61) reduce by decreasing SP1 binding. Furthermore, RNA binding proteins could modulate stability also determined RNA-pulldown assay. demonstrated YBX1, component coding region instability determinant (CRD)-mediated mRNA stabilization complex, promoted stability. DHX9, acted scaffold bridge YBX1 CARMN. Conclusions exerts an anti-cancer effect Akt-mTOR pathways. rs12517403 YBX1/DHX9 complex are influencing transcription cells. represents promising biomarker for diagnosis therapeutic target.

Язык: Английский

Процитировано

0

New insights into the pharmacological inhibition of SRF activity: Key inhibitory targets and mechanisms DOI

Daniel M. Wong,

Hongyu Qiu

Vascular Pharmacology, Год журнала: 2024, Номер 157, С. 107443 - 107443

Опубликована: Ноя. 23, 2024

Язык: Английский

Процитировано

0

The roles of LncRNA CARMN in cancers: biomarker potential, therapeutic targeting, and immune response DOI Creative Commons
Huafeng Liu, Xuewen Liu, Yanjun Lu

и другие.

Discover Oncology, Год журнала: 2024, Номер 15(1)

Опубликована: Дек. 18, 2024

Long non-coding RNAs (LncRNAs) are crucial regulators of gene expression and cellular processes, with significant implications for cancer research. This review focuses on the role LncRNA CARMN (Cardiac Arrest Regulated Myocyte Nuclear Protein) in various cancers. CARMN, originally identified its function cardiac tissues, has shown dysregulated several tumor types, including cervical, breast, colorectal, esophageal Its altered often correlates progression, metastasis, patient prognosis, suggesting potential as both a biomarker therapeutic target. In cervical cancer, CARMN's suppressor is highlighted by ability to inhibit cell proliferation, migration, invasion through interaction miR-92a-3p/BTG2 axis modulation Wnt/β-catenin signaling pathway. breast acts an enhancer RNA, affecting epithelial-mesenchymal transition metastasis regulating MMP2 via DHX9. The downregulation triple-negative associated enhanced sensitivity chemotherapy. colorectal regulated m6A methylation mutant p53, influencing growth miR-5683 FGF2. Lastly, genetic variations affect susceptibility, certain SNPs haplotypes either increased or decreased risk. Additionally, relationship between immune dynamics highlights surveillance therapy. Finally, we found that may regulate exhaustion microenvironment recruitment activation NK cells T cells, well modulating macrophage polarization. emphasizes diverse roles across different cancers diagnostic tool. Future research should address mechanistic details involvement validate clinical utility, explore combination existing treatments.

Язык: Английский

Процитировано

0